JP2017535600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535600A5 JP2017535600A5 JP2017543327A JP2017543327A JP2017535600A5 JP 2017535600 A5 JP2017535600 A5 JP 2017535600A5 JP 2017543327 A JP2017543327 A JP 2017543327A JP 2017543327 A JP2017543327 A JP 2017543327A JP 2017535600 A5 JP2017535600 A5 JP 2017535600A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- apilimod
- therapeutic agent
- vemurafenib
- melanoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 8
- 229950002889 apilimod Drugs 0.000 claims 6
- 201000001441 melanoma Diseases 0.000 claims 6
- HSKAZIJJKRAJAV-KOEQRZSOSA-N n-[(e)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound CC1=CC=CC(\C=N\NC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 HSKAZIJJKRAJAV-KOEQRZSOSA-N 0.000 claims 6
- 229960003862 vemurafenib Drugs 0.000 claims 6
- 229960002621 pembrolizumab Drugs 0.000 claims 5
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 102000000588 Interleukin-2 Human genes 0.000 claims 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 4
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 4
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 4
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 3
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 229960003301 nivolumab Drugs 0.000 claims 3
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 2
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- 102000004243 Tubulin Human genes 0.000 claims 2
- 108090000704 Tubulin Proteins 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- 108700025316 aldesleukin Proteins 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 229950002916 avelumab Drugs 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 229960005243 carmustine Drugs 0.000 claims 2
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 229960003901 dacarbazine Drugs 0.000 claims 2
- 229960003413 dolasetron Drugs 0.000 claims 2
- 229950009791 durvalumab Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229940080856 gleevec Drugs 0.000 claims 2
- 229960003727 granisetron Drugs 0.000 claims 2
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- 239000000138 intercalating agent Substances 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 229940083118 mekinist Drugs 0.000 claims 2
- 229960001346 nilotinib Drugs 0.000 claims 2
- 229960005343 ondansetron Drugs 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229960002131 palonosetron Drugs 0.000 claims 2
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims 2
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims 2
- 229960002508 pindolol Drugs 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 229940087463 proleukin Drugs 0.000 claims 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 2
- 229960001534 risperidone Drugs 0.000 claims 2
- 229940081616 tafinlar Drugs 0.000 claims 2
- 229940069905 tasigna Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- 229960004066 trametinib Drugs 0.000 claims 2
- 229960003048 vinblastine Drugs 0.000 claims 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- 229940034727 zelboraf Drugs 0.000 claims 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 229960002465 dabrafenib Drugs 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- GAJWNIKZLYZYSY-OKUPSQOASA-N methanesulfonic acid;n-[(e)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CC1=CC=CC(\C=N\NC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 GAJWNIKZLYZYSY-OKUPSQOASA-N 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 239000003909 protein kinase inhibitor Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229940068117 sprycel Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077127P | 2014-11-07 | 2014-11-07 | |
| US62/077,127 | 2014-11-07 | ||
| US201562115228P | 2015-02-12 | 2015-02-12 | |
| US62/115,228 | 2015-02-12 | ||
| US201562119540P | 2015-02-23 | 2015-02-23 | |
| US62/119,540 | 2015-02-23 | ||
| PCT/US2015/059502 WO2016073871A1 (en) | 2014-11-07 | 2015-11-06 | Apilimod for use in the treatment of melanoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535600A JP2017535600A (ja) | 2017-11-30 |
| JP2017535600A5 true JP2017535600A5 (enExample) | 2018-12-13 |
| JP6768682B2 JP6768682B2 (ja) | 2020-10-14 |
Family
ID=54548301
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543327A Expired - Fee Related JP6768682B2 (ja) | 2014-11-07 | 2015-11-06 | メラノーマの処置に使用するためのアピリモド |
| JP2017543330A Expired - Fee Related JP6716585B2 (ja) | 2014-11-07 | 2015-11-06 | 結腸直腸癌の処置に使用するためのアピリモド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543330A Expired - Fee Related JP6716585B2 (ja) | 2014-11-07 | 2015-11-06 | 結腸直腸癌の処置に使用するためのアピリモド |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190209576A1 (enExample) |
| EP (3) | EP3215159B1 (enExample) |
| JP (2) | JP6768682B2 (enExample) |
| KR (2) | KR20170098813A (enExample) |
| CN (2) | CN107206090A (enExample) |
| AU (2) | AU2015342876B2 (enExample) |
| BR (2) | BR112017009000A2 (enExample) |
| CA (2) | CA2966334A1 (enExample) |
| ES (1) | ES2734081T3 (enExample) |
| HU (1) | HUE044153T2 (enExample) |
| IL (2) | IL251904B (enExample) |
| MX (2) | MX2017006026A (enExample) |
| PL (1) | PL3215157T3 (enExample) |
| PT (1) | PT3215157T (enExample) |
| RU (2) | RU2739992C2 (enExample) |
| WO (2) | WO2016073884A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6855243B2 (ja) | 2014-01-24 | 2021-04-07 | エイアイ・セラピューティクス・インコーポレーテッド | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
| GB201408100D0 (en) * | 2014-05-07 | 2014-06-18 | Sec Dep For Health The | Detection method |
| HUE044557T2 (hu) | 2014-11-07 | 2019-11-28 | Ai Therapeutics Inc | Apilimod, veserák kezelésében történõ alkalmazásra |
| RU2018130070A (ru) * | 2016-01-21 | 2020-02-21 | Лэм Терапьютикс, Инк. | Биомаркеры для лечения рака при помощи апилимода |
| CA3039199A1 (en) * | 2016-10-12 | 2018-04-19 | AI Therapeutics, Inc. | Apilimod compositions and methods for using same in the treatment of alzheimer's disease |
| AU2018209164B2 (en) | 2017-01-17 | 2021-11-04 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| AU2019223014B2 (en) * | 2018-02-21 | 2024-10-17 | Orphai Therapeutics Inc. | Combination therapy with apilimod and glutamatergic agents |
| CA3167339A1 (en) | 2020-01-13 | 2021-07-22 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
| BR112023025552A2 (pt) * | 2021-06-11 | 2024-02-27 | Orphai Therapeutics Inc | Composições estabilizadas de apilimod e usos das mesmas |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6693097B2 (en) * | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
| EA009873B1 (ru) | 2004-02-06 | 2008-04-28 | Элан Фармасьютикалз, Инк. | Способ ингибирования роста опухоли и/или метастатического прогрессирования |
| EP1737845A4 (en) * | 2004-04-13 | 2010-07-21 | Synta Pharmaceuticals Corp | DISPLAY HEMMER OF IL-12 PRODUCTION |
| WO2006029385A2 (en) | 2004-09-08 | 2006-03-16 | Chelsea Therapeutics, Inc. | Quinazoline derivatives as metabolically inert antifolate compounds. |
| WO2006053112A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Process for preparing trisubstituted pyrimidine compounds |
| US7863270B2 (en) * | 2005-05-13 | 2011-01-04 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
| WO2006128129A2 (en) * | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| EP2385053B1 (en) | 2005-11-17 | 2013-10-02 | OSI Pharmaceuticals, Inc. | Intermediates for the preparation of fused bicyclic mTOR inhibitors |
| JP5215300B2 (ja) | 2006-07-12 | 2013-06-19 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 置換アシルアニリドおよびそれらの使用方法 |
| RU2438664C2 (ru) * | 2007-05-15 | 2012-01-10 | Пирамал Лайф Сайнсиз Лимитед | Синергическая фармацевтическая комбинация для лечения рака |
| US8402515B2 (en) | 2010-05-06 | 2013-03-19 | Jonathan Weizman | Apparatus and method for establishing a peer-to-peer communication session with a client device |
| US20110287018A1 (en) * | 2010-05-19 | 2011-11-24 | Philip Bosch | Methods of Treating Interstitial Cystitis |
| WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9295731B2 (en) * | 2013-04-01 | 2016-03-29 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
| JP6855243B2 (ja) * | 2014-01-24 | 2021-04-07 | エイアイ・セラピューティクス・インコーポレーテッド | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
| HUE044557T2 (hu) * | 2014-11-07 | 2019-11-28 | Ai Therapeutics Inc | Apilimod, veserák kezelésében történõ alkalmazásra |
| WO2016126707A1 (en) * | 2015-02-03 | 2016-08-11 | Lam Therapeutics, Inc. | Apilimod compositions and methods for using same |
| US20180078561A1 (en) * | 2015-03-31 | 2018-03-22 | Lam Therapeutics, Inc. | Active metabolites of apilimod and uses thereof |
| TWI746449B (zh) * | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
-
2015
- 2015-11-06 RU RU2017119066A patent/RU2739992C2/ru active
- 2015-11-06 EP EP15795319.1A patent/EP3215159B1/en active Active
- 2015-11-06 US US15/524,846 patent/US20190209576A1/en not_active Abandoned
- 2015-11-06 MX MX2017006026A patent/MX2017006026A/es unknown
- 2015-11-06 JP JP2017543327A patent/JP6768682B2/ja not_active Expired - Fee Related
- 2015-11-06 PT PT15795317T patent/PT3215157T/pt unknown
- 2015-11-06 ES ES15795317T patent/ES2734081T3/es active Active
- 2015-11-06 CA CA2966334A patent/CA2966334A1/en not_active Abandoned
- 2015-11-06 JP JP2017543330A patent/JP6716585B2/ja not_active Expired - Fee Related
- 2015-11-06 KR KR1020177015389A patent/KR20170098813A/ko not_active Ceased
- 2015-11-06 CA CA2966356A patent/CA2966356A1/en not_active Abandoned
- 2015-11-06 PL PL15795317T patent/PL3215157T3/pl unknown
- 2015-11-06 RU RU2017119064A patent/RU2731908C2/ru active
- 2015-11-06 CN CN201580072610.5A patent/CN107206090A/zh active Pending
- 2015-11-06 BR BR112017009000A patent/BR112017009000A2/pt not_active Application Discontinuation
- 2015-11-06 WO PCT/US2015/059526 patent/WO2016073884A1/en not_active Ceased
- 2015-11-06 HU HUE15795317A patent/HUE044153T2/hu unknown
- 2015-11-06 EP EP15795317.5A patent/EP3215157B8/en not_active Not-in-force
- 2015-11-06 AU AU2015342876A patent/AU2015342876B2/en not_active Ceased
- 2015-11-06 CN CN201580072613.9A patent/CN107427522B/zh not_active Expired - Fee Related
- 2015-11-06 US US15/524,841 patent/US10765682B2/en active Active
- 2015-11-06 MX MX2017006019A patent/MX374385B/es active IP Right Grant
- 2015-11-06 KR KR1020177015387A patent/KR20170101907A/ko not_active Ceased
- 2015-11-06 EP EP21186071.3A patent/EP3954375A1/en not_active Withdrawn
- 2015-11-06 BR BR112017009265A patent/BR112017009265A2/pt not_active Application Discontinuation
- 2015-11-06 WO PCT/US2015/059502 patent/WO2016073871A1/en not_active Ceased
- 2015-11-06 AU AU2015342863A patent/AU2015342863B2/en not_active Ceased
-
2017
- 2017-04-24 IL IL251904A patent/IL251904B/en active IP Right Grant
- 2017-04-24 IL IL251903A patent/IL251903B/en active IP Right Grant